BR112014020666A2 - usos de um inibidor de her3 - Google Patents
usos de um inibidor de her3Info
- Publication number
- BR112014020666A2 BR112014020666A2 BR112014020666A BR112014020666A BR112014020666A2 BR 112014020666 A2 BR112014020666 A2 BR 112014020666A2 BR 112014020666 A BR112014020666 A BR 112014020666A BR 112014020666 A BR112014020666 A BR 112014020666A BR 112014020666 A2 BR112014020666 A2 BR 112014020666A2
- Authority
- BR
- Brazil
- Prior art keywords
- her3 inhibitor
- her3
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261602239P | 2012-02-23 | 2012-02-23 | |
| PCT/EP2013/053562 WO2013124419A1 (en) | 2012-02-23 | 2013-02-22 | Her3 inhibitor for modulating radiosensitivity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014020666A2 true BR112014020666A2 (pt) | 2018-09-25 |
Family
ID=47749820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014020666A BR112014020666A2 (pt) | 2012-02-23 | 2013-02-22 | usos de um inibidor de her3 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10357566B2 (en:Method) |
| EP (1) | EP2817340B1 (en:Method) |
| JP (2) | JP6207531B2 (en:Method) |
| KR (1) | KR102051505B1 (en:Method) |
| CN (2) | CN104136464A (en:Method) |
| BR (1) | BR112014020666A2 (en:Method) |
| CA (1) | CA2865256C (en:Method) |
| ES (1) | ES2842201T3 (en:Method) |
| HK (1) | HK1199044A1 (en:Method) |
| IN (1) | IN2014KN01772A (en:Method) |
| WO (1) | WO2013124419A1 (en:Method) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102316892B1 (ko) * | 2019-12-20 | 2021-10-27 | 주식회사 베르티스 | 암의 진단용 조성물 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| TWI843989B (zh) | 2021-02-19 | 2024-06-01 | 美商美威高能離子醫療系統公司 | 用於粒子治療系統之支架 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| ATE188036T1 (de) * | 1990-01-18 | 2000-01-15 | Cura Nominees Pty Ltd | Glykoalkaloide |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
| CA2332331A1 (en) * | 1998-05-15 | 1999-11-25 | Francisco Robert | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| US20050239738A1 (en) * | 2000-11-17 | 2005-10-27 | Rupert Schmidt-Ullrich | Genetic inhibition of epidermal growth factor receptor function and carcinoma cell radiosensitization |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| ES2377206T3 (es) * | 2006-01-06 | 2012-03-23 | Ed Geistlich Sohne Ag Fur Chemische Industrie | Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam |
| US7838495B2 (en) * | 2007-04-27 | 2010-11-23 | University Of Maryland, Baltimore | Compositions and methods of use of EPB1, and ErbB3 binding protein |
| EP2138511A1 (en) * | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| US8139714B1 (en) * | 2009-06-25 | 2012-03-20 | Velayudhan Sahadevan | Few seconds beam on time, breathing synchronized image guided all fields simultaneous radiation therapy combined with hyperthermia |
| HUE035605T2 (en) | 2009-11-13 | 2018-05-28 | Daiichi Sankyo Europe Gmbh | Material and methods for treating or preventing HER-3 associated diseases |
-
2013
- 2013-02-22 ES ES13705987T patent/ES2842201T3/es active Active
- 2013-02-22 CA CA2865256A patent/CA2865256C/en active Active
- 2013-02-22 KR KR1020147023296A patent/KR102051505B1/ko active Active
- 2013-02-22 JP JP2014558121A patent/JP6207531B2/ja active Active
- 2013-02-22 US US14/380,268 patent/US10357566B2/en active Active
- 2013-02-22 EP EP13705987.9A patent/EP2817340B1/en active Active
- 2013-02-22 HK HK14112646.7A patent/HK1199044A1/xx unknown
- 2013-02-22 CN CN201380010479.0A patent/CN104136464A/zh active Pending
- 2013-02-22 IN IN1772KON2014 patent/IN2014KN01772A/en unknown
- 2013-02-22 CN CN201810314651.6A patent/CN108404129A/zh active Pending
- 2013-02-22 BR BR112014020666A patent/BR112014020666A2/pt not_active Application Discontinuation
- 2013-02-22 WO PCT/EP2013/053562 patent/WO2013124419A1/en active Application Filing
-
2017
- 2017-03-06 JP JP2017042264A patent/JP6368811B2/ja active Active
-
2019
- 2019-05-09 US US16/408,040 patent/US11351259B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017165711A (ja) | 2017-09-21 |
| US20150017096A1 (en) | 2015-01-15 |
| WO2013124419A1 (en) | 2013-08-29 |
| KR102051505B1 (ko) | 2019-12-03 |
| US20190388540A1 (en) | 2019-12-26 |
| CN108404129A (zh) | 2018-08-17 |
| ES2842201T3 (es) | 2021-07-13 |
| CA2865256A1 (en) | 2013-08-29 |
| IN2014KN01772A (en:Method) | 2015-10-23 |
| CN104136464A (zh) | 2014-11-05 |
| CA2865256C (en) | 2020-02-11 |
| US10357566B2 (en) | 2019-07-23 |
| EP2817340B1 (en) | 2020-12-09 |
| EP2817340A1 (en) | 2014-12-31 |
| JP6207531B2 (ja) | 2017-10-04 |
| JP2015509944A (ja) | 2015-04-02 |
| KR20140123544A (ko) | 2014-10-22 |
| JP6368811B2 (ja) | 2018-08-01 |
| US11351259B2 (en) | 2022-06-07 |
| HK1199044A1 (en) | 2015-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2902029A4 (en) | RET INHIBITOR | |
| HUE036259T2 (hu) | Inhibitor vegyületek | |
| PT3459942T (pt) | Inibidores de adn-pk | |
| LT2895484T (lt) | Gliukozilceramido sintazės inhibitoriai | |
| CO7010838A2 (es) | Compuestos de imidazopirrolidinona | |
| SMT201600114B (it) | Inibitori di beta-secretasi | |
| EP2912019A4 (en) | HETEROARYL HEMMER OF PDE4 | |
| PT3068786T (pt) | Compostos de pirazolopirimidina | |
| CO6880068A2 (es) | Aminoquinazolinas como inhibidores de quinasa | |
| AR092198A1 (es) | Derivados de pirazolopirimidinas | |
| DK2804858T3 (da) | Metalloenzym-inhibitorforbindelser | |
| DK2895033T3 (da) | Mønsterdannelse til konstruerbart redskab | |
| ME02985B (me) | Prolekovi inhibitora amino-hinazolinske kinaze | |
| HUE051648T2 (hu) | CCR3-gátlók használata | |
| EP2811909A4 (en) | ULTRASOUND SCAN | |
| EP2858975A4 (en) | FBXO3 INHIBITORS | |
| BR112014022506A2 (pt) | variantes de cbh1a | |
| DK2740750T3 (da) | Polyurethanbaserede klæbemidler | |
| DK2888228T3 (da) | Inhibitorer af CD40-TRAF6 interaktion | |
| EP2892529A4 (en) | USES OF (-) - PERHEXILINE | |
| ES1080381Y (es) | Fachada de medios | |
| BR112014020666A2 (pt) | usos de um inibidor de her3 | |
| EP2923383A4 (en) | LIGHT DETECTION | |
| EP2842958A4 (en) | NAPHTHOBISTHIADIAZOLDERIVAT | |
| EP2831063A4 (en) | Schweinfurthin-ANALOG |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: DAIICHI SANKYO EUROPE GMBH (DE) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |